Does First-in-Class FOP Drug Approval Transform the Bull Case For Regeneron ...

Regeneron Pharmaceuticals received FDA approval for Pasatru, the first-in-class treatment for the ultra-rare disease fibrodysplasia ossificans progressiva (FOP), which supports its broader diversification strategy beyond its core drugs. While this approval strengthens Regeneron's pipeline, the near-term investment outlook still hinges on the performance of EYLEA HD and Dupixent amidst pricing and payer pressures.

This Wire brief sits within Fusion42's coverage of Biotech, and 8 sources have reported it between 19 Aug 2026 and 23 Aug 2026.